Rocket Pharmaceuticals, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Rocket Pharmaceuticals, Inc. (RCKT) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $39.13 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-10
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $39.13M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $39.67M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $40.21M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $40.75M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $39.13M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $39.67M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $40.21M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $40.75M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $41.29M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $41.83M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $42.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $42.90M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $43.44M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $43.98M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $44.52M 10-K · filed 2025-02-27 |
| 2023-09-30 | $45.06M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $45.59M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $46.13M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $46.66M 10-K · filed 2024-02-27 |
| 2022-09-30 | $46.88M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $47.41M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $47.95M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $48.48M 10-K · filed 2023-02-28 |
| 2021-09-30 | $49.01M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $49.51M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $50.31M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $50.52M 10-K · filed 2022-02-28 |
| 2020-09-30 | $52.55M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $49.25M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $47.54M 10-Q · filed 2020-05-08 |
| 2020-03-15 | $47.70M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |